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Abstract
Cystic fibrosis (CF) is an autosomal recessive genetic disorder involving a mutation in the
CF transmembrane conductance regulator protein (CFTR), which causes dysfunctional transport
of chloride ions across cell membranes. CF affects multiple body systems and few of its symptoms
include chronic cough, difficulty breathing, obstructive airway disease, bacterial pulmonary
infections, maldigestion, malabsorption, pancreatitis, and male infertility. Until recently, treatment
options have been limited to alleviating symptoms, but a new classification of drugs, CFTR
modulators, provide an opportunity to slow the progression of the disease and improve clinical
outcomes. The effect of CFTR modulators may be attributed to the reduction of persistently
colonizing bacteria in CF lungs. Though, the effects of modulators on microbial communities
colonizing the CF lung remains unknown, specifically with common respiratory pathogens such
as Pseudomonas aeruginosa and Staphylococcus aureus. Particularly, previous CF studies have
been limited in scope due to focusing on only one type of modulator and by using low-yield
sequencing techniques. To address this gap, we seek to study the changes in CF respiratory
pathogens of patients initiating CFTR modulator therapy at Nemours Hospital using long-read
metagenomic sequencing (Oxford Nanopore) of longitudinally collected respiratory samples. We
have optimized a protocol for host DNA depletion and microbial metagenomic sequencing to
characterize the respiratory microbiome. This study focuses on utilizing these sequencing data to
compare the lung microbiome among two healthy controls to pre-CFTR-treatment microbial
communities of two recruited CF patients.
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Hypothesis and Specific Aims
Cystic Fibrosis is an autosomal recessive genetic disorder involving a mutation in the
CFTR protein (Cystic Fibrosis Transmembrane Conductance Regulator), which causes
complications in the lungs, pancreas, and other organ systems and has affected 30,000 people in
the US (1). The CFTR gene is located on chromosome 7 and codes for CFTR protein, which
regulates the proper flow of water and chloride ions in and out of epithelial cells lining the lungs
and other organs; dysfunctional chloride channels affect the transport of ions across cell
membranes. CF causes variety of symptoms and majority of its effects are seen in the respiratory
system as it causes frequent coughs, shortness of breath, recurrent lung bacterial infections, and
chronic sinopulmonary infections leading to lung function decline and shortened life span of CF
patients (1). Treatment of respiratory bacteria pathogens often requires frequent and continued
antimicrobial use (2). Until recently, available treatment options have been more directed towards
alleviating CF symptoms, but a new classification of drugs called CFTR modulators provide an
opportunity to slow the advancement of the disease for qualifying patients (1). CFTR modulators
have significantly improved clinical outcomes among CF patients. Some of these impacts may be
credited to reductions in bacterial colonization and subsequent exacerbation requiring clinical
intervention. An observational study of CF patients with G551D mutation treated with Ivacaftor,
a type of CFTR modulator, revealed a 35% reduction in Pseudomonas aeruginosa
positivity ;however, there were few observed effects on Staphylococcus aureus and other common
CF pathogens (3). Three other smaller studies assessing the impact of Ivacaftor on the lung
microbiome of CF patients with G551D mutation have yielded conflicting results (4-6). However,
these studies have been limited in scope due to targeting only one type of modulator therapy, only
focusing on select respiratory bacteria, or using poorly resolved methods to assess microbial
1

populations. A second limitation of previous studies pertains to methods for characterizing
microbiota. To date, majority of studies assessing the CF lung microbiome have used 16S rRNA
sequencing technique and a few have utilized short-read sequencing with Illumina. Subsequently,
little is known about the impact of CFTRs on microbial communities colonizing the CF lung or on
epidemiologically important pathogens such as P. aeruginosa and S. aureus. Further, it is unclear
whether observed changes to airway microbiology are due to antimicrobial properties of the drug,
as some evidence has suggested, or because of lung function improvement. This knowledge gap
may impede clinical decision-making related to modulator therapy in conjunction with
antibacterial management of respiratory colonizers and pathogens. To address these gaps, we
sought to study changes in CF respiratory pathogens in patients initiating and maintained on CFTR
modulator therapy at the Nemours Children’s Hospital (NCH) Pediatric CF Center in Orlando, FL
using Nanopore metagenomic techniques. The scope of this thesis will focus on the
characterization of microbial diversity within and between CF patients before they initiate CFTR
modulator therapy and will compare these findings to healthy samples. These data will later be
used to investigate how lung microbial communities change after initiation of therapy and how
these changes are associated with long-term outcomes. Using metagenomic whole-genome
sequencing (WGS) of microbial communities in the CF lung, we will characterize diversity,
composition, and evolution (such as any mutations) of these microorganisms over time. Later,
these changes will be correlated with clinical outcomes. We hypothesize that microbial diversity
is reduced among patients before the initiation of therapy, with a predominance of select
opportunistic pathogens in the respiratory flora. Subsequent studies will test the hypothesis that
CFTR modulators increase the microbial bacteria diversity by reducing the carriage of common
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CF bacteria or removal from the lung microbiome. We will test our first hypothesis in the following
specific aim:
Aim 1- Characterize the diversity of airway microbial communities among pediatric cystic fibrosis
patients using metagenomic sequencing. We will test the hypothesis that microbial diversity
among CF patients is reduced compared to that of healthy controls.
A.) Assess the microbial diversity (alpha diversity) of CF patients and compare them to healthy
controls.
B.) Determine the prevalent species (beta diversity) between CF patients and compare them to
healthy controls.

Research Design and Methods
We propose a prospective, longitudinal cohort study of pediatric CF patients seeking care
at NCH Pediatric CF center. There are currently 105 patients in the registry of NCH CF clinic out
of the total 123 pediatric CF patients. 45 patients are already on CFTR modulators and we expect
the number to increase to 55 by next year (2021). We seek to enroll 10 patients initiating CFTR
modulator therapy within the following 9-24 months as well as patients that are currently on dualcombination therapy who qualify for transitioning to triple-combination therapy. Subsequently,
we will seek to follow the recruited patients for 12 months before and after initiation or change of
CFTR modulator therapy – allowing for 4 pre- and 4 post-treatment visits Patients already
receiving triple-combination therapy or who will not be able to be followed for at least 9 months
prior to starting treatment (3 pre-treatment observations) will be excluded. In addition, patients
participating in clinical trials that will potentially confound observations of this study will be
excluded per determination of the clinical lead. This study focuses on the initial characterization
of the pre-treatment microbial communities of two pediatric CF patients.
3

Institutional Review Board: The proposal for this study was submitted to be reviewed by the board
of reviewers at Nemours Children’s Hospital and after an extensive one-year long process, we
were able to receive IRB approval to initiate this study.
Data collection: NCH clinical research staff will approach qualifying patients during routine
quarterly visits and consent will be obtained from parents/children for study. Respiratory samples
(sputum, throat swabs) collected during routine quarterly visits or Bronchoalveolar lavage
performed for clinical care will be stored at 4°C and transported to the laboratory of Dr. Azarian
for processing and sequencing as described below. In addition, respiratory samples and clinical
isolates collected during acute exacerbations requiring inpatient treatment will be similarly
processed. Retrospective chart review will be used to identify clinical and microbiological history
including CFTR mutations, previously identified respiratory bacteria, treatment history, antibiotic
use, FEV1 values, and frequency of pulmonary exacerbations. Prospectively, for each visit, chart
review will be used to obtain FEV1 values, frequency of exacerbations, radiology reports,
antibiotic use, and modulator treatment data.
Aim 1- Characterize the diversity of airway microbial among pediatric cystic fibrosis
patients using metagenomic sequencing. Using metagenomic data longitudinally collected from
patients before modulator therapy, we will test the hypothesis that microbial diversity among CF
patients is reduced compared to that of healthy controls. We will perform host DNA depletion and
metagenomic sequencing on respiratory samples collected during the study using an optimized
protocol as presented in the preliminary data (15). Statistical analysis will be conducted using
RStudio v1.0.143 with R v3.3.19.
Host DNA Depletion: Performing ‘host DNA depletion’ is one of the critical steps in our
methodology since it allows us to focus on the microbial population only. In 2019, Charalampous
4

and colleagues published a protocol for rapid diagnosis of lower respiratory infections using
Nanopore-based clinical metagenomics, which we now propose to employ here (15). An
innovative component of their protocol was saponin-based host cell depletion. Working with the
authors, we have adapted this protocol for use in our laboratory. First, Respiratory sputum samples
(400µl) will be centrifuged at 8000 xg for 5 min, then the supernatant will be carefully removed,
and the pellet resuspended in 250µl of PBS. For throat specimens, swabs will be placed in 150µl,
vortexed and subsequently processed. Saponin which is a detergent used to promote host cell lysis
will be added to yield a final concentration of 2.2% and incubated at room temperature (RT) for
10 min. Next, 350µl of water will be added and incubated at RT for 30 seconds. Then, 12µl of 5M
NaCl will be added to the mixture and samples will be centrifuged at 6000 xg for 5 min, with the
supernatant removed and the pellet resuspended in 100µl of PBS. Then, 100µl HL-SAN buffer
will be added, followed by 10µl HL-SAN DNase. The sample will be incubated for 15 min at 37°C
with shaking at 800 RPM on an Eppendorf Thermomixer for host DNA digestion. Finally, the
host-DNA depleted samples will be washed two times with PBS (800µl, 1 ml). After each wash,
the sample was centrifuged at 6000 xg for 3 min, the supernatant discarded, and the pellet
resuspended in PBS.
Bacterial growth detection: In order to assess the growth and visualize the type of bacteria in the
clinical sample, we will plate 100 µl of the sample on each of the following plates: Blood Agar
(BA), CHROMagar Staph aureus, and CHROMagar Pseudomonas. The plates will be incubated
for 24 hours and the growth of all 3 plates will be recorded. Then, from each plate three colonies
will be picked and sub-cultured on new CHROM-SA and CHROM-PA plates. The following day,
the SA colonies will be verified via Staphyloslide test. Lastly, three isolates from each of the SA
and PA plates will be stored in -80-degree freezer.
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Bacterial Lysis and DNA Extraction: After the final wash step of the host depletion, the pellet will
be re-suspended in 500µl of bacterial lysis buffer, transferred to a bead-beating tube and beadbeaten at maximum speed (30 oscillations per second) for 3 min in a Tissue Lyser bead-beater to
ensure the release of DNA from difficult-to-lyse organisms. The sample will be centrifuged at
20,000 xg for 1 min and ~230µl of supernatant transferred to a fresh Eppendorf tube. The volume
will be topped-up with 170µl of bacterial lysis buffer and 20µl of proteinase K added. Samples
will then be incubated at 65°C for 5 min with shaking at 800 RPM on an Eppendorf Thermomixer.
Lastly, DNA will be extracted from samples using the Qiagen DNeasy Blood and tissue kit
according to the noted instruction.
DNA quantification and quality control: DNA quantification will be performed using the high
sensitivity dsDNA assay kit on the Qubit 3.0 Fluorometer. DNA quality and fragment size (PCR
products and MinION libraries) will be assessed using the TapeStation 4200 automated
electrophoresis platform with the Genomic ScreenTape and a DNA ladder.
Sequencing: Extracted metagenomic DNA will be carried out using the ONT MinION with R9.4.1
flow cells and MinIT real-time compute module. Library preparation and sequencing will be
performed according to the manufacturer’s instructions for the Rapid Low-Input by PCR
Sequencing Kit (SQK-RLI001and Rapid PCR Barcoding Kit (SQK-RPB004).
Data analysis: ONT MinKNOW software will process raw sequencing data and generate basecalls. Human DNA reads will be removed from base-called data using Minimap2 to align to the
human hg38 genome prior to subsequent analysis. The Metagenomic Rapid Annotations using
Subsystems Technology (MG-RAST) pipeline will be used for analysis of MinION data to identify
the composition of microbial populations (83). Metagenomic data will be used to determine
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changes in microbial diversity (alpha-diversity) and composition (beta-diversity) of the respiratory
microbiome (32).
Hypothesis testing: Metagenomic data will be used to determine changes in microbial diversity
(alpha-diversity) and composition (beta-diversity) of the respiratory microbiome as well as
differences in bacterial growth dynamics and prevalence of antibiotic resistance determinants.
Alpha diversity values were obtained through MG-RAST and the Vegan package in R was used
to calculate the Beta diversity between the samples.
1.) Shannon Diversity Index (SDI, alpha-diversity) – SDI, which accounts for both species’
richness and evenness, will be calculated from metagenomic data for each observation (33,34).
Using a mixed model test for two means in a 2-level hierarchical design, we will compare the SDI
values (35).
2.) Bray-Curtis dissimilarity (BCD, beta-diversity) – Compositional differences will be quantified
using BCD (36, 37). Significance will be determined using 10,000 permutations of the Mantel
test, a non-parametric statistical method which measures the correlation between dissimilarity
matrices (38).

Background
The epithelial cells lining the lungs contain a protein on their surface called CFTR, which
is responsible for the airway surface liquids (ASL) by transporting sodium and chloride ions in
and out of the cells (7). The ASL has two layers: liquid and a mucous layer. Liquid layer provides
an environment for the cilia to bath in and the mucous layer traps the bacteria (7). In healthy
individuals’ lungs, through the movement of chloride ions out of the cells, water is drawn from the
epithelial cells which leads to hydration of the ASL layers and efficiently removing the bacteria
by the movement of cilia (7). On the other hand, In CF lungs the hydration of the airway surface
7

liquids is diminished which results in think and sticky mucus and provides the perfect environment
for bacterial colonization and infection (7).

Figure 1. Airway Surface Liquid Regulation in CF lungs vs. Healthy lungs. Image obtained from (7).

Treatment and care to improve quality of life plays a major role in the life of cystic fibrosis
patients. Since most of the debilitating CF symptoms affect the respiratory system, the main focus
for treatment options is directed towards improving the respiratory issues. Removing the
accumulated mucus that is colonized with bacteria is one of the significant steps in decreasing the
lung inflammation (8). One of the major treatment options for the CF patients in the past 60 years
has been utilizing antibiotics for bacterial infections, thereby reducing tissue damage from
inflammation and slowing down the decline in lung function (7). The new advancement in CF
treatment has been the discovery of a new classification of drugs called CFTR modulators which
provide an opportunity to slow the progression of the disease for more than 90 percent of patients
(1). There are multiple CFTR modulator drugs approved by the U.S. Food and Drug
Administration (FDA), all of which are oral tablets that have the potential to affect not only the
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lungs but also the sinuses and pancreas. Of the 30,000 persons living with CF in the USA, an
estimated 15,000 qualify for CFTR modulator treatment and this number is projected to increase
to 90 % of this population with the approval of triple combination therapy (9). Identifying the
effects of CFTR modulators on airway microbial communities will facilitate tailoring long-term
management and more generally elucidate the dynamics of microbial communities in the CF
airway.
Currently, there are conflicting data on the dynamics of CFTR modulators and airway
microbiology. Data are limited largely to a single CFTR-potentiator, Ivacaftor, and studies have
been limited in sample size, methodology, or scope. For example, microbiome studies have largely
used only 16S rRNA based profiling, which lacks the resolution of whole-genomic metagenomics
(4,6). Unlike 16S rRNA based profiling, metagenomics offers the opportunity to study
communities at the strain level resolutions (11,12). Other studies have focused on specific
pathogenic bacteria using MLST to PFGE molecular typing (3,6). This limits the ability to 1)
accurately determine whether the strain present prior to treatment is the same afterwards,
especially in settings where a common MLST or PFGE is prevalent in the hospital or community
at large, and 2) assess the pathogen genomic changes in the bacteria that allow it to persist during
a time of changing lung ecology. Furthermore, culture and molecular diagnostics are unable to
identify uncommon bacteria and antibiotic resistance mechanisms with high confidence. Here, we
will overcome these limitations with using nanopore long read technology to enable sampling of
the microbial communities and the reconstruction and study of the constituent genomes. Nanopore
sequencing has previously been used in pilot studies to identify bacterial and viral pathogens in
clinical samples (13-15) as well as rapidly identify antibiotic resistance (16). A major
methodological advancement has been the recent development of respiratory sample preparation
9

protocols for host nucleic acid depletion, which have allowed nanopore-based metagenomic
sequencing and analysis (15). Combining single-isolate and nanopore sequencing, we will be able
to further assess changes in microbial growth dynamics, which is not possible using solely 16S
profiling data (17). By assessing the growth dynamics of the respiratory microbial community, we
will be able to assess their physiological status and provide context to the variations observed in
their composition over time (18). Further, few studies have assessed intrahost adaptation of
persistently carried respiratory bacteria in CF (e.g., P. aeruginosa (19-20), Burkholderia spp. (2125), and S. aureus (25-28)), and none have considered CFTR modulators. In a recent analysis of
long-term intrahost evolution of S. aureus among cystic fibrosis patients, we found evidence of
strain adaptations for persistence (29). We will apply the same methodology to investigating
multiple microbes in the context of intervention. Together, leveraging these advances provides
significant innovations from prior work. The results from this study will have direct application to
current treatment practices and lay the foundation for larger multi-center studies. In addition to
addressing gaps related to modulator treatment, our results will elucidate more general microbial
dynamics in CF airways as well as have implications for the future use of nanopore-based
sequencing technology for rapid pathogen diagnostics and antibiotic resistance detection in CF
patients.

Classes of Cystic Fibrosis
To date, more than 2,000 mutations have been found in the CFTR gene that can cause CF
(30, 69). Over the years, scientists have used several different ways of categorizing these mutations
into different classes (39). The classical model had organized the CF classes into five categories,
but the most recent classification system groups these mutations into 6 classes (40, 68). The first
three classes are more severe and the last three classes are noted to be less severe.
10

Class Type

Type of mutations

Class I

Protein production mutations

Class II

Protein processing mutations

Class III

Gating mutations

Class IV

Conduction mutations

Class V

Insufficient protein mutations

Class VI

Reduction in CFTR protein stability

Table 1. This table illustrates the six CF classes along with mutations in each class.

Figure 2. Functional classification of CFTR mutations with examples of more prevalent mutations of each class and therapy
type. Image obtained from (37)

Class I: Protein Production Mutation
Class I mutation results from nonsense and splice mutations that preclude synthesis of full-length
CFTR protein (40). Nonsense mutations in CFTR gene result in an early stop signal that causes
the termination of production of the CFTR protein which leads to a non-functional CFTR protein
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(65). Splice mutations interfere with the ability of the cell to correctly read the instructions for
making the CFTR protein and results in a truncated nonfunctional CFTR protein. Some mutations
commonly seen in this class are G54X, W1282X, and R553X, and according to the Cystic Fibrosis
Foundation, 22% of CF patients have the class I mutation (39).

Class II: Protein Processing Mutations
Class II mutations include abnormally folded CFTR proteins that are degraded by the cell quality
control system (38). This is when the CFTR protein is created, but the misfolding does not allow
it to go to the cell surface. Mutations leading into insertion or deletion of amino acids causes the
CFTR protein to not form the proper tertiary structure (39,40). Per Cystic Fibrosis Foundation,
88% of patients have class II mutation and the most common CF mutation F508del is classified
in this category (39). The F508del mutation removes a phenylalanine amino acid at the position
508 in the CFTR protein which does not allow the CFTR protein to make the correct tertiary
structure. Additionally, there are missense mutations that can cause processing problems by
lowering the quantity of CFTR proteins at the cell surface (39).

Class III: Gating Mutations
Class III mutants are when CFTR reaches the cell surface but due to diminished ATP hydrolysis
it does not exhibit channel gating (40). The CFTR protein is shaped like a tunnel with a gate
where cells open the gate when chloride ions need to flow through the channel. Gating mutations
result in locking the gate and preventing the flow of chloride ions (39, 40). Class III mutations
are seen in 6% of the CF population (41).
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Class IV: Conduction Mutations
Class IV mutations reduce the chloride ion flow through the channel (40). In order for CFTR to
function properly, chloride has to move quickly and smoothly through the protein's channel (39).
Some mutations change the shape of the CFTR protein, thus hindering the movement of chloride
ions (39). It’s important to note that in class IV mutations, there is a proper CFTR protein that is
able to reach the cell surface, but the function of the channel is faulty due to reduced chloride
conductance (40, 43). 6% of CF population has been noted to have Class IV mutation and some of
the common mutations in this class are D1152H, R347P, and R117H (43).

Class V: Insufficient Protein Mutations
Class V mutations cause a decreased quantity of CFTR protein at the cell surface. Several reasons
can lead to this such as: alternative splicing, production of a limited amount of CFTR proteins, and
a low number of properly working CFTR proteins at the cell surface (39). Insufficient quantities
of functional proteins at the cell surface leads to transportation of fewer chloride ions in and out
of the cell linings (66). Class V mutations account for 5% of the CF population (39).

Class VI: Reduction in CFTR proteins stability
Class VI mutants result in instability of CFTR at the plasma membrane by reducing its
confirmational stability (67). In this mutation, the CFTR at the plasma membrane is removed and
sent to lysosome during recycling (40, 42). rF508del and Q1412X are couple of mutations found
in this class.
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Treatment with CFTR modulators
CFTR modulators target the main defect in the CFTR mutation. There are several modes
of action of CFTR modulators, but their main goal is to restore the wild type CFTR protein or at
least to modulate the mutant protein and improve their functionality (44,45). CFTR modulators
have shown to have significant clinical benefits such as improvements in weight, growth, lung
function and lowering the risk of pulmonary exacerbations (54). CFTR modulators are commonly
referred to as ‘personalized’ treatment since each type of modulators are prescribed to patients
with a specific mutation that the modulator has been designed for. Currently, there are four groups
of CFTR modulators approved by the U.S. Food and Drug Administration (FDA). The modulators
are in a form oral tablets and have the potential in improving the lung function as well pancreas
and sinuses (46).
Classification of CF mutations in 6 distinct classes is advantageous in making a
corresponding classification for CFTR modulators designed for repairing the defects in each
mutation class (47, 66). The CFTR mutation in each class leads to a different dysfunctional
etiology and thereby different CFTR modulator types are developed to address each of the
etiologies. The first three classes of mutations are considered ‘severe’ in that they are associated
with little or no protein function at the epithelial surface and due to affecting a larger pool of CF
patients, they have been the priority in developing CFTR modulator therapies for (48). Following
are the main types of CFTR modulators: 1) Potentiators. 2) Correctors. 3) Amplifiers. 4) “Next
Generation”
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1. Potentiators
In January 2012, FDA approved the first CFTR modulator called Ivacaftor (Kalydeco), a
type of potentiator. Potentiators bind and potentiate the opening of CFTR protein at the cell surface
and help chloride ions flow through the CFTR protein channel (49). Ivacaftor is designed for
patients with Class III and Class IV mutations. Class III are gating mutations in which altered
protein at the membrane surface has locked the gate; therefore, ‘potentiators’ hold the gate on the
CFTR protein and allow chloride ions to flow through (10). Ivacaftor is also used in individuals
with G551D mutation found in Class II and involves 4% of CF patients. Recently, ivacaftor was
approved by the FDA for another eight gating (Class III) mutations which together with G551D
account for total of ~5% of all CF patients (50). Due to its mechanism of action, ivacaftor is
effective only in patients who have some degree of functioning CFTR protein production. Thereby,
Ivacaftor is not suitable for patients who have the homozygous F508del mutation or any mutation
classes that entirely prevent the production of the CFTR protein (55). Ivacaftor was approved after
achieving promising results from various studies, with the focus of one of the studies being patients
6 to 11 years old. Davies and collogues performed a randomized, double-blind, placebo experiment
with patients of ages 6–11 with a G551D mutation on at least one allele (56). Fifty-two patients of
6 years or older were randomly given either ivacaftor or placebo. During the treatment patient’s
forced expiratory volume (FEV1) which is the amount of air the patient can exhale in one second
was measured to test their lung function. Patients with chronic obstructive lung diseases or CF
patients tend to have lower FEV values. Percent predicted forced expiratory volume in 1 second
(ppFEV1) results after 24 weeks of treatment indicated that ivacaftor caused a 12.6% increase
from baseline in comparison to a 0.1% increase seen in the placebo group (59). Per study results,
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Ivacaftor reached its more significant effect on improving the lung function by day 15 of the
treatment and the improvement continued through week forty-eight (56).
2. Correctors
Correctors were designed to facilitate the CFTR protein processing and increase the
quantity of CFTR protein at the plasma membrane. They are two types of correctors: Lumacaftor
and Tezacaftor. Correctors aid in forming the correct tertiary shape of the CFTR protein so the
protein is able to reach the cell membrane and transport chloride. Correctors are an appropriate
treatment choice for patients with class II CF mutations (10). F508del mutation, one of the most
common CF mutations belongs to Class II mutation. Almost half of the CF patients who have two
copies of the F508del mutation are qualified to take the ‘corrector’ modulator therapy (10). Data
obtained from initial in vitro testing, indicated that lumacaftor could assist the “trafficking” of
CFTR protein and allow the proteins to reach the cell membrane and transport chloride ions (57).
In a subsequent phase 2a study, eighty-nine CF patients with homozygous F508del
mutation were randomly assigned to either receive placebo or one daily dose of lumacaftor four
weeks (58). People with CF have more chloride in their sweat than healthy individuals, therefore
sweat chloride test is one of the golden tests for CF. In this study, Lumacaftor demonstrated a
significant mean difference in sweat chloride testing in the experiment group compared to placebo
(49). Lumacaftor had positive effects on sweat chloride test, but it did not have significant effect
on the respiratory symptoms, the lung function, and FEV1 by itself (49). There is another corrector
called tezacaftor which functions similarly to lumacaftor by allowing the CFTR protein make the
right tertiary shape, traffic to the cell surface, and stay there longer.
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Combining Two Modulators
After achieving not very impressive results with implementing Lumacaftor and Ivacaftor
alone to treat the homozygous F508del CF patients, scientists decided to combine these two
modulators (49). In July 2015, the FDA approved the lumacaftor/ivacaftor (Orkambi) combination
therapy which is developed for patients 2 years and older who have two copies of the F508del
mutation (52, 55). The rationale behind combining these two modulators is that lumacaftor will
help with the trafficking of the CFTR protein, and ivacaftor will assist the CFTR protein to remain
open and transport chloride ions. In some situations, the proteins that do reach the cell surface do
not open adequately to allow chloride to pass out of the cell; in this case, utilizing a corrector
mixed with a potentiator to hold the gate open allows enough chloride to flow through the channel
to reduce the symptoms of CF.
The combinations of lumacaftor/ivacaftor (Orkambi) and tezacaftor/ivacaftor (Symdeko)
are utilized in treating people with homozygous F508del mutation (10, 53, 55).
Tezacaftor/ivacaftor combination is also approved for treatment of people ages 6 and older with a
single copy of one of 26 specified mutations published on the CF foundation (10). Per CF
foundation, patients treated with tezacaftor/ivacaftor in clinical trials showed a 6.8% improvement
in the lung function (10). The difference between the two approved combinations is that the
tezacaftor/ivacaftor combination has been reported to have fewer side effects and drug interactions
than lumacaftor/ivacaftor (51).
3. Amplifiers
Amplifiers are currently being developed and tested and are not yet available. The goal of
amplifiers is increase quantity of the produced CFTR proteins. Amplifiers could be used in
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combination with potentiators and correctors to further improve the function of CFTR protein and
allow even more chloride to flow across the cell membrane (10).
4. “Next Generation”
Ivacaftor and lumacaftor were approved first; therefore, they are more commonly referred
to as “first-generation modulators”. Tezacaftor, approved in February 2018, is also considered a
first-generation modulator. “Next-generation” modulators are the newer and potentially the more
effective CFTR modulators. The next-generation CFTR modulators focus on various problems
caused by the F508del mutation to improve CFTR folding and increase the amount of CFTR
proteins reaching the cell surface (10). The objective behind designing the “next generation”
modulators is to develop drugs that can be approved for the CF patients that could have not
benefitted from the previous modulators including individuals with a single F508del mutation (10,
39). VX-659 and VX-445 are two types of “next-generation” correctors with a different structure
and mechanism of action than the first-generation correctors lumacaftor and tezacaftor (59, 60).
The goal of “next generation” modulators is to be able to be used in treating the CF patients that
were previously not qualified for any other modulators. Scientists have shown that the combination
of next generation modulators with correctors is better at increasing the quantity of CFTR proteins
at the cell surface that solely using correctors (59, 60).
Triple Combination Therapy
As of October of 2019, the FDA has approved the use of Trikafta, which is a triple
combination therapy for treatment of CF that could potentially treat 90% of the patients (64). Per
Dr. Jeffrey Leiden, president and CEO of Vertex Pharmaceutical, Trikafta is the first medication
that can treat the underlying cause of the disease for about 6,000 patients (65). These triple drug
combination therapies along with next-generation CFTR correctors target the patients with only
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one F508del mutation (62). Since 90% of the CF patients have at least one copy of F508del
mutation.
Triple combination is when the two next generation correctors: VX-445 and VX-659 are
each used in combination with tezacaftor and ivacaftor (61). Trikafta was approved after a two
Phase 3 trials in the AURORA program. This study included more than 500 CF patients of ages
12 and older (63). Data from both studies showed significant improvements in lung function
(ppFEV1) in patients given Trikafta. The first study tested VX-445 combined with
tezacaftor/ivacaftor (Symdeko) in CF patients of 12 years and older who had only one copy of the
F508del mutation. After 28 days of treatment the results indicated a 13.8 percent increase in lung
function compared to the placebo group (65).
The second study wanted to test the effectiveness of tezacaftor/ivacaftor alone compared
to VX-445 combined with tezacaftor/ivacaftor. In this study CF patients of 12 year and older with
two copies of the F508del mutation participated. Following 28 days after treatment, participants
who received the triple combination had a 10 percent improvement in lung function compared to
those who only received the tezacaftor/ivacaftor (62, 63). Approval of Trikafta is a significant
milestone for the CF community since now more CF patients will be qualified for treatment with
CFTR modulators that could greatly benefit their health, decrease the CF symptoms, and improve
their quality of life.

CF lung microbiome vs healthy lung microbiome
Historically, it was believed that the lung is sterile. However, decades of respiratory
culture-independent protocols for bacterial identification and high throughout sequencing
techniques has debunked this myth (71). Healthy lung microbiome prominently consists of
Proteobacteria, Firmicutes, and Bacteroidetes at the phylum level and Pseudomonas, Prevotella,
19

Fusobacteria and Veillonella at the genus level (70). CF is one of the chronic lung diseases that
the disease course is significantly influenced by the changes in the composition of the lung
microbiome (71). Thereby, in the absence of the normal lung microbiota, the patient is more
susceptible to bacterial infections with organisms such as Listeria monocytogenes and Klebsiella
pneumonia (72, 73).
Most common pathogens in the CF lungs include P. aeruginosa, S. aureus, B. cepacia, H.
influenza, S. maltophillia, and MRSA (7, 70). According to the British Society for Immunology,
the lungs of about 50% of CF patients during infancy are predominantly occupied by
Staphylococcus aureus, which continues to decline as the patient gets older (7). By the age of 18,
gram negative Pseudomonas aeruginosa becomes the bacteria predominantly colonizing the CF
lungs in about 80% of patients (7). Out of all of the pathogens in the CF airway, P. aeruginosa is
the one most strongly correlated with causing respiratory decline (75). Therefore, it is critical to
gain a more precise understanding of the effect of restoring the CFTR function on the presence or
absence of P. aeruginosa.

Figure 3. Prevalence of the most predominant organisms in the CF lung as a function of age. Obtained from 74.
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Effect of CFTR modulators on lung microbiome
To date, there have been a few small cohort studies that focused on assessing the changes
in the lung microbiome of CF patients after treatment with a modulator; thereby the data available
are limited. In the paper published in 2015 by Bernarde et al, they assessed the airway of three
pediatric CF patients, with G551D mutation treated with Ivacaftor, by utilizing qPCR and 16s
rRNA sequencing (4). Important note is that none of the patients had chronic Pseudomonas
aeruginosa infection and they were followed for 13 months after the initiation of the treatment.
The analysis showed that no significant changes were identified before and after the treatment (4).
Another longitudinal study was done in 2012-2013 in G551D CF patients of 6 years and
older that were being treated with Ivacaftor (5). 133 patients with known P. aeruginosa infection
completed this study, and they were assessed at the baseline and then at 1, 3, and 6 months
following the Ivacaftor treatment. The analysis showed improvement in FEV1 %, body mass,
sweat chloride testing, and mucociliary clearance. They also noted a significant reduction in the
detection of P. aeruginosa infection 6 months after starting the therapy (5, 75). To gain a more
comprehensive analysis, the researchers performed a P. aeruginosa-specific qPCR, which didn’t
indicate a significant decrease in sputum abundance. They also performed a sputum inflammatory
marker test and microbiota analysis by 16S sequencing on 14 patients. The findings showed a
combination of traditional CF bacteria and no significant changes in the bacterial diversity nor in
the inflammatory markers were noted after the Ivacaftor treatment (5, 75). However, the interesting
finding was the overall downward trend of the combined abundance of the traditional CF microbes
and an increase in the abundance of Prevotella, which is one of the bacteria commonly colonizing
the healthy lungs (75).

21

A subsequent study in 2016 by Hisert et al. included 12 adult CF patients with G551D
mutation and chronic airway infection who were qualified for Ivacaftor therapy (6). Patients were
followed longitudinally and 16S sequencing of sputum bacteria content, lung CTs, lung function,
and inflammatory marker tests were done before and after the initiation of Ivacaftor therapy (6).
Eight of the patients in this study had chronic P. aeruginosa infections. It was noted that the P.
aeruginosa content in their sputum sample began decreasing at day 2 and the average number of
colonies forming units (CFUs) of P. aeruginosa decreased by 10-fold by day 7 of the study (6).
The analysis of the microbiome also indicated a general decrease in the abundance of P.
aeruginosa, with an increase in the abundance of the nontraditional CF organisms such as
Streptococcus, Prevotella, and Veillonella (6). Though, the interesting finding to note is that none
of the patients in the study became consistently negative for P. aeruginosa infection, and after the
first year of the study the density of P. aeruginosa rebounded (6).
In a following study in 2016-2017 Peleg et al focused on investigating the effect of
Ivacaftor on CF lung microbiome during the early treatment period (76). Twenty G551D CF
patients participated in this double blind, placebo, crossover study of Ivacaftor for the first 28 days
of treatment. Sputum microbial content was assessed with 16S rRNA sequencing and qPCR
techniques and the clinical symptoms were tested via respiratory function and blood testing (76).
The findings indicated no significant changes in total load of P. aeruginosa and no changes in the
composition of the lung microbiome during treatment with Ivacaftor in comparison to the pretreatment lung microbiome (76). But they noted that over time the sputum microbiome variation
was greater between subjects that within them (75, 76). Thus far, studies that have focused on
assessing the CF lung microbiome have been done using the less-resolved techniques such as 16S
rRNA sequencing, thereby, the data gathered are inconsistent and limited. Therefore,
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understanding the impact of CFTR treatment on the CF lung microbiome with more advanced
techniques is critical to inform of the CF community of both the function of the modulators and
also help the physicians in strategizing treatment plans to manage the CF infections with
modulators in conjugation to antibiotics.

Approaches to characterizing lung microbiome
There are various methods available for sequencing samples such as 16s rRNA:
pyrosequencing, Illumina, and ONT MinION. The factor that adds to the significance of our study
is using Nanopore based sequencing technique for metagenomic analysis of the microbiome,
which has never been done before on CF lung microbiome. Most common technique used for
analysis of CF microbiome has been the 16s rRNA sequencing technique which takes advantage
of the 16S rRNA housekeeping genes on the 30S ribosome subunit as a genetic marker. This is
due to being present in almost all bacteria and having a large enough size for informatics purposes.
However, the 16S rRNA technique is limited due to short read lengths, sequencing errors, limited
resolution, and the difficulty in assessing the diversity according to a single gene marker (80).
Illumina sequencing is one of the Next Generation Sequencing (NGS) technologies.
Illumina sequencing generates high throughput data with high accuracy rate of 99%. The data
outputs short length reads and depending on the type of the platform used the read length can reach
300 base pairs in each run. Illumina follows a sequencing by synthesis (SBS) approach, which
detects each of the bases as they are added to the growing DNA chain (77). Illumina sequencing
is done simultaneously on every cluster on a flow cell which is a solid surface with millions of
different molecules (81). The Illumina sequencing method is similar to Sanger sequencing except
it uses dNTPs with a reversible terminator block that blocks further polymerization so only one
nucleotide can be added by the polymerase (81). In SBS each of the reversible terminating
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nucleotides are fluorescently labeled with a different color and attached to a different fluorophore
for easy identification as they pass the flow cell (77).

First, the primer anneals to its

complementary strand and DNA polymerase begins making a copy of the DNA using the
fluorescently labeled nucleotide blocks. The fluorophores act as a blocking group in a way that
DNA polymerase cannot add a new base until the fluorophore is removed (77). Once the
fluorophore for the added base is recorded by the computer, the fluorophore is removed, and DNA
polymerase resumes its activity. Although the Illumina technology is able to detect the variants
that were missed in the traditional Sanger sequencing, it has a major disadvantage of outputting
short length reads, which makes it difficult to complete the whole genome (79).
Another type of sequencing technology, which is the method utilized in this study, is Oxford
Nanopore technology (ONT), which is one of the newest and most powerful method of rapid
generation of sequencing data. The advantage of nanopore sequencing data is that the read length
(fragment length of DNA) is significantly longer than the more commonly used Illumina (2,50070,000 bp compared to 100-300 bp), which we can use to identifying species level data as well as
the presence of genes of interest (e.g., antibiotic resistance genes) with high confidence.
Additionally, it is portable, the cost is affordable, and only requires a computer to analyze the data
(82). Some of the disadvantageous of Nanopore are its lower throughput and lower accuracy read
compared to Illumina with accuracy rate of 92-97% (82). Nanopore follows a direct sequencing
method. It has biological pores that are inserted into a synthetic polymer membrane which is
immersed in an electrolyte solution that generates an ionic current through the pores (82). As
molecules enter the nanopore, the DNA pauses temporarily in one nucleotide interval. During this
pause, the MinION identifies the nucleotides bases according to the changes that they cause in the
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current of the nanopores (78). The nucleotides are characterized, and the data streams are then
passed through the software that generate the data.

Results
We recruited two healthy individuals to participate in our study. We performed five
replicates of host-depletion on healthy respiratory samples from sputum and oropharyngeal
swabs obtained from two individuals (MJ and TA), varying microbial cell-lysis approaches.

Table 2. Human and bacterial DNA qPCR results for healthy-donor sputum and throat swab samples with and without host
DNA depletion.

Probe- and SYBR-Green-based qPCR was performed on undepleted and depleted samples to
quantify human DNA and the bacterial 16S rRNA V3-V4 gene fragment. In all five replicates, we
observed 10 to 50-fold depletion of host DNA with minimal loss of microbial DNA. We selected
two samples, MJ3 (sputum) and TA4 (oropharyngeal) for nanopore-based sequencing, producing
1.87 and 1.72 gigabases of data for MJ3 and TA4, respectively (read length N50 3,400 bp). After
de-multiplexing and filtering reads by quality and length, reads were mapped to the human
reference genome hg38, and unmapped microbial reads were exported for subsequent analysis.
For MJ3, 76% of reads (1.43 Gb) were microbial; for TA4, 96.5% (1.67 Gb) were microbial.
Microbial reads were analyzed using the EPI2ME WIMP (What’s in my Pot) pipeline (31). For
MJ3, 29 genera were identified at a relative abundance level greater than 0.1%, dominated by the
genus Streptococcus, and 28 species were classified at an abundance >0.5%. For TA4, 29 genera
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were also identified with an abundance >0.1%, dominated by the genus Prevotella, and 40 species
were classified at a relative abundance >0.5%. We demonstrate successful depletion of host DNA
followed by nanopore based metagenomic sequencing to characterize the airway microbiome.
Additionally, the raw sequencing data were uploaded on MG-RAST which is an open-source web
application built for performing quality control, analyzing, and annotating metagenomic results.
MG-RAST automatically assigns functional sequences that belong to the metagenome by
performing comparison to datasets and then provides phylogenic trees, bar plots, and graphs of
the analyzed metagenome (83). We obtained pie charts and bar plots from MG-RAST which
provided information about the abundance of the species in each sample. Figure 4 is a pie chart
obtained from MG-RAST which shows the most abundant species found in the healthy sample
MJ3. As seen in the pie chart, Streptococcus with 40.29% is the most abundant organism in this
individual, followed by Prevotella with 15.76%, Fusobacterium with 10.24% and Veillonella with
6.27%, which are all the organisms commonly found in healthy lung microbiome. Per MG-RAST,
the dataset for MJ3 contains 468,700 sequences totaling 1,425,422,904 base pairs with an average
length of 3,041 bps. The alpha diversity for this set if 90 species.
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Figure 4. The pie chart obtained from MG-RAST shows the percentages of the species found in the healthy sample MJ3.

MG-RAST also provided bar plots showing the most abundant taxa in order. Figure 5 is the bar
plot for MJ3. The bar plot here shows the same results indicated in the pie chart, with Streptococcus
having the highest abundance followed by Prevotella.

Figure 5. Bar plot obtained from MJ3 healthy sample which shows the abundance of taxa in order from most abundant to least
abundant.
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Similar figures were obtained from MG-RAST for TA4, the second healthy sample. The pie chart
provided for TA4 (Figure 6) illustrates Prevotella with occupying 28.55 % of the composition is
the most abundant organism in this sample followed by Streptococcus with 23.98%. The bar plot
for TA4 (Figure 7) also demonstrated Prevotella to have the highest abundance followed by
Streptococcus in a close margin. This dataset contains 476,322 sequences totaling 1,668,623,029
base pairs with an average length of 3,503 bps. The α-diversity of this data set is 80 species.
Comparing the two healthy sample, we can conclude that they both are occupied by organisms
expected to be found in healthy lung microbiomes. Additionaly, the alpha diversity which
measures both richness and evenness within each sample was reported. As species richness
increases so does the alpha diversity. The alpha diversity for MJ3 is 90 and for TA4 is 80, which
are relatievly close to one another and higher that then diversities obtained for the CF patients
which supports the hypothesis that diversity within CF patients is lower in compariosn to healthy
individuals.

Figure 6. The pie chart obtained from MG-RAST shows the percentages of the species found in the healthy sample TA4.
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Figure 7. Bar plot obtained from TA4 healthy sample which shows the abundance of taxa in order from most abundant to least
abundant.

The most abundant species in MJ3 is Streptococcus with 40.29% and the most abundant organism
in TA4 is Prevotella with 28.55%. An interesting observation is that in MJ3, the most abundant
organism, Streptococcus, is occupying a significant portion of the microbiome. And there is a
noticeable difference between composition of Streptococcus with 40.29% and the second most
abundant organism, Prevotella, with percentage of 15.76. Same observation cannot be made for
TA4, since the percentages of the composition of each organism in TA4 sample’s microbiome are
a lot closer to one another, with the most abundant organism, Prevotella, occupying 28% of the
lung microbiome and the second most abundant organism occupying 23% of the composition. We
also obtained Krona charts for each of the sample. Krona is a visualization tool that allows for
hierarchical data to be shown in multi-layered pie charts (84). The Krona resembles a pie chart, in
which the chart subdivides each class into a sector which is overlaid with smaller sections that
represent the constituents of the previous sector (84). Here, the Krona pie charts obtained are
following a taxonomix hierarchy in which the first section in the middle of section is starting from
Bacteria, and then as we go up from the middle circle we see the domain, phylum, class, and lastly
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genus level species. Figure 8.A represents the Krona pie chart for MJ3 and figure 8.B represents
the Krona chart for TA4. The Krona charts follow a taxonomic order, with Firmicutus being the
most abundent at the phylum level in both samples. We know from the MG-RAST data that
Streptococcus is the most abundent organism in MJ3, and by further analyzing the data with the
Krona chart, we can conclude that within the genus of Streptococcus, the most abundant species
is Streptococcus parasanguinis with 9% abundance.

Figure 8.A. Krona pie chart for MJ3 that shows the percentage abundance of the organism found in the microbiome in a
taxonomic order.
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Figure 8.B. Krona pie chart for TA4 that shows the percentage abundance of the organism found in the microbiome in a
taxonomic order.

The Krona pie chart obtained for TA4, indicates Firmicutes to have the highest abundancein
phylum level. In the species level, Prevotella melaninogenica is shown to have the highest
abundancewith 12%.
Similar analyses were done to obtain pie chart, bar plots and krona charts for the two CF
samples. Figure 9.A shows the pie chart obtained from MG-RAST for the first CF patient (CF-1),
which notes Prevotella to be occupying the most of the lung microbiome (45.05%), followed by
Streptococcus (26.50%), and then Veillonella (11.66%). The bar plot (Figure 9.B) also shows
Prevotella to be the leading taxa with the highest abundance. The Krona chart becomes very useful
here (Figure 9.C) because we were able to zoom in and look more in detail into the species level.
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The first CF patient that we obtained throat swabs from had known history of Pseudomonas
Auroginosa infection and by zooming into the taxonomy level in the Krona chart we were able to
find Pseudomonas that is occupying 5% of the patient’s lung microbiome. Also, after careful
analysis into the genus level organisms and further looking into the Pseudomanas genus, we
noticed Pseudomonas aeruginosa species to be occupying 18% of the Pseudomanas genus (Figure
9.D)

Figure 9.A. The pie chart obtained from MG-RAST shows the percentages of the species at genus level found in the first CF
patient (CF-1).

Figure 9.B. Bar plot obtained from CF-1 sample which shows the abundance of taxa in order from most abundant to least
abundant.
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*

Figure 9.C. The Krona pie chart for the first CF patient (CF-1) that shows the percentage abundance of the organism found in
the microbiome in a taxonomic order. A * is put next to Pseudomonas species for ease of detection.

*

Figure 9.D. Zoomed in cross section of the Krona chart for CF-1 which shows a more detailed percentage composition of the
Pseudomonas genus.
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The pie chart obtained from MG-RAST and the bar plot for the second CF patient (CF-2) were
analyzed. The most abundunt organism in CF-2 is Prevotella (53.47%) followed by Veillonella at
17.03% and then Streptococcus with 8.75%.

Figure 10.A. The pie chart obtained from MG-RAST shows the percentages of the species at genus level found in the second CF
patient (CF-2).

Figure 10.B. Bar plot obtained from CF-2 sample which shows the abundance of taxa in order from most abundant to least
abundant
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Figure 10.C. The Krona pie chart for CF-2 that shows the percentage abundance of the organism found in the microbiome in a
taxonomic order.

Figure 10.D. Zoomed cross section of the Krona pie chart of CF-2 showing the abundance of Burkholderia cenocepacia with
yellow highlights.
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When analyzing the lung microbiome of the second CF sample which was obtained from
a 2-year old male patient’s oropharyngeal swab, the krona pie chart provided a detailed look into
the species level of the organisms. In the initial glance, Bacteroidetes has the highest abundance
in the phylum level followed by Firmicutes. After further investigation into the Proteobacteria
phylum and the Betaproteobacteria class, we found 1% composition of Burkholderia which is one
of the microbes known to cause infections in the CF lungs. Additional analysis into Burkholderia,
we indicated Burkholderia cenicepcia occuppying 8% of the whole Burkholderia genus (Figure
10.D). This patient (CF-2) also noted to have Pseudomonas genus occupying 1 % (Figure 10.E)
of his lung microbiome, with Pseudomonas aeruginosa occupying 21% of the Pseudomonas genus
(Figure 10.E)

*

Figure 10.E. Zoomed in cross section of the Krona chart for CF-2 which shows a more detailed percentage composition of the
Pseudomonas genus. The pie chart on the left shows the Pseudomonas abundance. The Chart on the right is the shows the
abundance of Pseudomonas Aeruginosa species within the Pseudomonas genus.

Subsequently, MG-RAST was used to find the alpha diversity values for the CF samples.
CF-1 had alpha diversity of 43 and CF-2 had alpha diversity of 45. These values are significantly
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lower than the alpha diversity indices obtained for the healthy samples which were 80 and 90 for
MJ and TA consecutively. This illustrates that the diversity of the lung microbiome decreases
significantly in CF lungs pre-CFTR treatment in comparison to healthy lungs. Beta diversity
measures the changes in the composition between the two samples and is commonly measured
with Bray-Curtis dissimilarity index. In Bray-Curtis, the values outputed are between 0 and 1.
Values close to 0 mean that the samples are identical or that they share the same species; and
values closer to 1 mean that the samples having nothing in common. Table 2 shows the Beta
diversity indices between each of the sample. As seen the Beta diversity index between the two
healthy samples is 0.23, which inidicates that these two samples share similar species composition.
The Beta diversity between the two CF samples is calculated to be 0.31, which also suggests that
these two CF samples are more similar to one another. When comparing CF to healthy samples,
we see that the beta diversity between them is higher than the within group comparison, showing
that there is more dissimilarity in species composition between CF and healthy samples (Table 3).
This pattern is somewhat expected, since there is more similarities when comparing one healthy
lung microbiome to another healthy one, as oppose to comparing the CF microbiome composition
to healthy ones.

TA4
MJ3
CF1
CF2

TA4
0.23
0.52
0.46

MJ3
0.23
0.54
0.58

CF1
0.52
0.54
0.31

CF2
0.46
0.58
0.31
-

Table 3. Beta diversity indices for each sample obtained by using Vegan Package in R. The B diversities shows that two CF
samples are more similar to one another and the two healthy samples are also more similar to one another.
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Conclusion
Understanding the composition of the lung microbiome in CF patients pre- and post-CFTR
treatment is of upmost significance in saving CF patient’s lives, further improving their treatment
plan, and expanding the use of CFTR modulators by allowing the clinicans in better understanding
the impact of the modulators on CF lungs. In this study, we used the novel Nanopore technology
to perform metagenomic sequencing on two pediatric CF patients seeking care at Nemours
Children’s Hospital pre-CFTR treatment with triple combination modulators. Nanopore MinION
technology allowed us to obtain a comprehensive look into the lung microbiome by providing
species level resolution at an unprecedentent level of detail. We then compared the findings in CF
patients with two healthy individuals. We assessed the alpha diversity within each sample and the
composition differences between each sample. Our findings detected P. aeruginosa, B. cenicepcia,
H. Influenzia, and S. aureus in the lung microbiome of CF patients, with traditional bacteria
expected to be seen in healthy lungs occupying the lung microbiome of the two healthy samples.
Subsequently, comparing the alpha diversity indices supported the hypothesis that the microbial
diversity is reduced among CF patients before the initiation of therapy compared to that of healthy
controls. Understanding the differences in the lung composition of people with CF in comparison
to healthy individuals, is significant in improving the quality of the care and treatment plan tailored
for each CF patient. By interrogating the genomes of persistently carried bacteria collected before
and after initiation CFTR treatment, we will be able to identify signatures of recent adaptation,
which has implications for the treatment of all persons living with CF and will have direct
application to current treatment practice.
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